1721: The Observed Correlation between Testosterone Levels and Prostate Specific Antigen Values in a Large Screening Population

2007 ◽  
Vol 177 (4S) ◽  
pp. 573-573
Author(s):  
E. David Crawford ◽  
Colin O'Donnell ◽  
Al B. Barqawi
Keyword(s):  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Testosterone Levels ◽  
Screening Population

scholarly journals Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone

2019 ◽  
Vol 50 (1) ◽  
pp. 58-65 ◽  
Author(s):  
Yasushi Nakai ◽  
Nobumichi Tanaka ◽  
Isao Asakawa ◽  
Satoshi Anai ◽  
Makito Miyake ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Biochemical Recurrence ◽  
Specific Antigen ◽  
Testosterone Levels ◽  
Psa Bounce ◽  
125I Brachytherapy ◽  
Psa Nadir ◽  
Free Rate

Abstract Background Because patients with prostate-specific antigen (PSA) bounce do not experience biochemical recurrence (BCR) until PSA bounce occurs, the period until PSA bounce ends can be considered the so-called lead-time bias. Therefore, we evaluated differences in BCR-free rate in prostate cancer patients who were BCR-free 4 years after 125I-brachytherapy alone. Furthermore, we evaluated predictors for PSA bounce and the correlation between testosterone and PSA bounce. Methods From 2004 to 2012, 256 patients with prostate adenocarcinoma underwent 125I-brachytherapy alone. PSA and testosterone levels were monitored prior to 125I-brachytherapy, at 1, 3, 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60 months after 125I-brachytherapy and yearly after 5-year follow-up. PSA bounce was defined as ≥0.2 ng/ml increase above the interval PSA nadir, followed by a decrease to nadir or below. Results BCR-free rate in patients with PSA bounce (100% 7-year BCR-free rate) was significantly better (P < 0.044) than that in patients without PSA bounce (95.7% 7-year BCR-free rate) in patients who were BCR-free 4 years after 125I-brachytherapy alone (n = 223). Age was the only predictor (odds ratio: 0.93, 95% confidence interval: 0.88–0.98, P = 0.004) for PSA bounce (n = 177). The testosterone level at PSA bounce was significantly higher (P = 0.036) than that at nadir before PSA bounce (87 cases). Conclusions Patients with PSA bounce had good BCR-free rate even in patients who were BCR-free 4 years after 125I-brachytherapy alone. Testosterone levels were higher at PSA bounce; increased testosterone levels may be a cause of PSA bounce.

scholarly journals Relationship Between Prostate-specific Antigen, Age, and Body Mass Index in a Prostate Cancer Screening Population

2012 ◽  
Vol 35 (5) ◽  
pp. 490-492 ◽  
Author(s):  
Luke E. Pater ◽  
Kimberly W. Hart ◽  
Brian J. Blonigen ◽  
Christopher J. Lindsell ◽  
William L. Barrett
Keyword(s):  
Prostate Cancer ◽  
Body Mass Index ◽  
Cancer Screening ◽  
Prostate Specific Antigen ◽  
Body Mass ◽  
Prostate Cancer Screening ◽  
Specific Antigen ◽  
Screening Population

THE INCIDENCE OF PROSTATE CANCER IN A SCREENING POPULATION WITH A SERUM PROSTATE SPECIFIC ANTIGEN BETWEEN 2.5 AND 4.0 NG./ML.: RELATION TO BIOPSY STRATEGY

2001 ◽  
Vol 165 (3) ◽  
pp. 757-760 ◽  
Author(s):  
RICHARD J. BABAIAN ◽  
DENNIS A. JOHNSTON ◽  
WILLIAM NACCARATO ◽  
ALBERTO AYALA ◽  
VIJAYA A. BHADKAMKAR ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Serum Prostate Specific Antigen ◽  
Screening Population

1844 ASSOCIATION OF STATIN USE TO SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN A SCREENING POPULATION

2010 ◽  
Vol 183 (4S) ◽  
Author(s):  
Bulent Akduman ◽  
Daniel J. Tandberg ◽  
Colin O'Donnell ◽  
Alexa Hughes ◽  
Mark A. Moyad ◽  
...  
Keyword(s):  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Serum Prostate Specific Antigen ◽  
Screening Population ◽  
Statin Use

scholarly journals Estimation of Prostate Cancer Probability by Logistic Regression: Free and Total Prostate-specific Antigen, Digital Rectal Examination, and Heredity Are Significant Variables

1999 ◽  
Vol 45 (7) ◽  
pp. 987-994 ◽  
Author(s):  
Arja Virtanen ◽  
Mehran Gomari ◽  
Ries Kranse ◽  
Ulf-Håkan Stenman
Keyword(s):  
Prostate Cancer ◽  
Logistic Regression ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Clinical Findings ◽  
Explanatory Variables ◽  
Rectal Examination ◽  
Screening Population ◽  
Total Psa

Abstract Background: Despite low specificity, serum prostate-specific antigen (PSA) is widely used in screening for prostate cancer. Specificity can be improved by measuring free and total PSA and by combining these results with clinical findings. Methods such as neural networks and logistic regression are alternatives to multistep algorithms for clinical use of the combined findings. Methods: We compared multilayer perceptron (MLP) and logistic regression (LR) analysis for predicting prostate cancer in a screening population of 974 men, ages 55–66 years. The study sample comprised men with PSA values >3 μg/L. Explanatory variables considered were age, free and total PSA and their ratio, digital rectal examination (DRE), transrectal ultrasonography, and a family history of prostate cancer. Results: When at least 90% sensitivity in the training sets was required, the mean sensitivity and specificity obtained were 87% and 41% with LR and 85% and 26% with MLP, respectively. The cancer specificity of an LR model comprising the proportion of free to total PSA, DRE, and heredity as explanatory variables was significantly better than that of total PSA and the proportion of free to total PSA (P <0.01, McNemar test). The proportion of free to total PSA, DRE, and heredity were used to prepare cancer probability curves. Conclusion: The probability calculated by logistic regression provides better diagnostic accuracy for prostate cancer than the presently used multistep algorithms for estimation of the need to perform biopsy.

scholarly journals Breast Tissues in Transsexual Women–A Nonprostatic Source of Androgen Up-Regulated Production of Prostate-Specific Antigen

1999 ◽  
Vol 84 (9) ◽  
pp. 3313-3315
Author(s):  
Victor H. H. Goh
Keyword(s):  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Serum Testosterone ◽  
Serum Levels ◽  
Androgen Therapy ◽  
Testosterone Levels ◽  
The Mean ◽  
Breast Tissues ◽  
Serial Measurements

The present study made use of the female transsexual model and sought to evaluate the contributions of the ovarian, endometrial, and breast tissues to the androgen up-regulated production of prostate specific antigen (PSA). Serum levels of PSA were significantly raised in female transsexuals before surgery, after long-term androgen therapy (mean ± se = 35.3 ± 6.2 pg/mL) when compared with female transsexuals before surgery, but with no androgen therapy (mean ± se = 1.53 ± 0.25 pg/mL). In addition, in androngenized female transsexuals, after surgery, concentrations of PSA (mean ± se = 14.5 ± 2.8 pg/mL) were significantly lowered compared with androngenized female transsexuals after surgery, but the levels were, nevertheless, significantly higher than in normal females. Monthly im injection of 250 mg Sustanon-250 to female transsexuals had raised serum testosterone levels to within the male range. In five subjects, in whom serial measurements were taken, serum testosterone levels were greatly raised 24 h after the testosterone therapy; the mean level (±se) was 19.5 ± 2.1 ng/mL. But in spite of these high testosterone levels, serum PSA levels (mean ± se= 2.2 ± 0.9 pg/mL) were not significantly raised. However, after 12 months of androgen therapy, the mean (±se) PSA level in these five subjects was 47 ± 11.6 pg/mL and was significantly higher than the mean level in nonandrogenized female transsexuals. The present study confirmed that high levels of testosterone were able to up-regulate PSA production in women. This up-regulation of PSA production is both a dose- and time-dependent process. Furthermore, the evidence indicates that breast tissues are possibly a nonprostatic source of androgen up-regulated production of PSA women.

Sign in / Sign up

Export Citation Format

Share Document